PanGenetics and Lay Line Genomics (LLG) entered into a collaboration in the field of therapeutic antibodies for the treatment of pain. Under the terms of the collaboration agreement, LLG granted PanGenetics exclusive rights to Hu-alphaD11, a humanized antibody against nerve growth factor (NGF) that has shown promising effects in preclinical animal models of inflammatory and chronic pain.
The companies will work together on the preclinical program and PanGenetics will assume full responsibility for the clinical development and commercialization of Hu-alpha-D11. In addition to research funding and an upfront payment, LLG will receive undisclosed milestone payments and royalties on commercial sales.
“With the preclinical support of LLG, it is our clear goal to have Hu-alphaD11, which will be renamed PG110, ready for human trials in 2008,” says Kevin Johnson, CEO of PanGenetics. “The focus of this program on nervous system disease provides important synergy with our PG102 program, for which we are currently planning a clinical study in MS patients.”